OBJECTIVE: To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. RESEARCH DESIGN AND METHODS: This 52-week, multicenter, parallel-arm study (primary end point: 26 weeks) randomized patients (2:2:2:1) to dulaglutide 1.5mg, dulaglutide 0.75mg, exenatide 10g, or placebo (placebo-controlled period: 26 weeks).

READ FULL ARTICLE Curated publisher From Diabetesjournals